DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension

Information source: Facet Biotech
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Cardene® I.V. (Drug)

Phase: Phase 2

Status: Withdrawn

Sponsored by: Facet Biotech


To define the relationship between Cardene I. V. dose, serum concentrations, and blood pressure reduction in pediatric subjects with hypertension.

Clinical Details

Official title: A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene I.V. in Pediatric Subjects With Hypertension

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Mean percent change in SBP (Systolic Blood Pressure) from baseline during the 30-minute Randomized, Placebo-controlled Infusion Phase for each dose level of Cardene I.V. compared to placebo.

Secondary outcome: 1) Mean percent change in SBP and DBP between various phases of dosing. 2) Proportion of subjects requiring additional antihypertensive medications during the treatment period. 3) Mean effective dose of Cardene I.V.

Detailed description: Children with acute hypertensive episodes are frequently treated with the same marketed drugs as adults. Few drugs are specifically indicated for use in children with severe hypertension. Cardene I. V. has been widely used in children with severe hypertension without specific dosing recommendations for children in the labeling. This study is designed to examine the pharmacokinetics, pharmacodynamics, safety, and efficacy of using Cardene I. V. to reduce blood pressure (BP) in children with hypertension and will provide important information to guide use in pediatric patients.


Minimum age: 2 Years. Maximum age: 16 Years. Gender(s): Both.


Inclusion Criteria:

- Evidence of Stage 1 or Stage 2 systolic hypertension at the time of screening.

- Male or female subjects, ages ≥2 to ≤16 years.

- Females who meet either of the following criteria:

- Non-childbearing potential , as documented by:

1. a medical history of non-menstruation or 2. surgical sterility from oophorectomy and/or hysterectomy. * A history of tubal ligation or evidence of a sterile sexual partner is insufficient evidence of non-childbearing potential.

- Childbearing potential: provide a negative urine pregnancy test within 24 hours

of administration of study drug and agree to utilize effective contraception or remain abstinent during the entire treatment and follow-up periods of the study.

- Signed informed consent provided by an authorized subject representative and assent

from subject, if feasible (based on local Institutional Review Board (IRB)/ethics panel requirements). Exclusion Criteria:

- Subjects with seizures, altered state of consciousness, chest pain, facial palsy or

intracranial hemorrhage at the time of screening.

- Receiving antihypertensive medication within a duration specified prior to screening.

- Treatment with cimetidine within 10 hours prior to dosing with study drug.

- Any known or suspected allergy to nicardipine hydrochloride.

- A calculated Glomerular Filtration Rate (GFR) under 30 mL/min/ 1. 73 m2 as calculated

using the Schwartz formula and the associated K values.

- Known history of severe aortic stenosis.

- Known history of severe left ventricular dysfunction.

- Known history of severely impaired hepatic function with portal hypertension.

- Liver function test (AST or ALT) results greater than or equal to twice the upper

limit of normal.

- Receiving maintenance hemodialysis at screening or anticipated to require

hemodialysis within 12 hours following initiation of treatment with study drug.

- Receiving a blood transfusion at screening or anticipated to require blood

transfusions within 12 hours following initiation of treatment with study drug.

- Lack of appropriate intravenous (I. V.) access.

- Inability to tolerate a large-volume I. V. infusion.

- Any other condition or prior therapy, which, in the opinion of the investigator,

would make the subject unsuitable for this study.

- Participation in any phase of another clinical research study involving the

evaluation of another investigational drug or device within 30 days before randomization.

Locations and Contacts

Beverly Hills, California 90211, United States

Miami, Florida 33145, United States

Additional Information

Starting date: September 2007
Last updated: March 15, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017